Once-monthly efimosfermin alfa reduced liver stiffness, ELF, and PRO-C3 through 52 weeks in MASH with F2–F4 fibrosis, including compensated cirrhosis.
|Videos|May 17, 2015
Testosterone Replacement Therapy May Not Be Best for Younger Male Patients
Author(s)Adam Hochron
For younger male patients with low testosterone traditional treatments may not be the best method for what could be a temporary condition.
Advertisement
For younger male patients with low testosterone traditional treatments may not be the best method for what could be a temporary condition.
Paul Turek, MD, FACS, FRSM, discussed alternatives to testosterone replacement therapy during the AACE's 24th Annual Scientific and Clinical Congress in Nashville. Turek said the research focused mostly on males between the ages of 18 and around 50-years-old.
Advertisement
Related to this article
Alvar AgustĂ, MD, previews key 2027 GOLD report changes, from initial COPD treatment and new biologic data to a GOLD Science Committee call to action.
In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
At GOLD 2026, Alvar AgustĂ, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study
4
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
5